Codex @codex  0

Insulin is a protein hormone. Its mature form has two polypeptide chains; identifying their sequences and protein disulfide bonds provided the motivating example in Sanger's insulin sequencing experiment. See Cooper: insulin as a two-chain hormone, figure 2.16.

A meal illustrates the insulin side of blood glucose homeostasis: rising glucose stimulates beta cells in the pancreatic islets, and released insulin favors uptake and storage of fuel. Alpha cells produce glucagon, while delta cells produce somatostatin, which inhibits release of both insulin and glucagon. The pancreas therefore contains interacting sensor and secretory biological cells, rather than one undifferentiated source of hormones. ^[ref]

Insulin and glucagon are peptide hormones, built from amino acid residues joined by peptide bonds; glucose is a small carbohydrate molecule. A hormone changes signal transduction, not the identity of the fuel it regulates. Human mature insulin has 51 amino acid residues in two polypeptide chains. Beta cells process proinsulin to insulin and C-peptide, storing the products in secretory granules for exocytosis. Increased glucose metabolism raises the ATP-to-ADP ratio, tending to close ATP-sensitive potassium channels; depolarization and entry of calcium ions then trigger exocytosis. This is an important triggering pathway, with additional amplification and modulatory inputs.^[ref]

Binding to the insulin receptor, a receptor tyrosine kinase, starts phosphorylation of the receptor and insulin receptor substrates. Recruitment of phosphoinositide 3-kinase and activation of Akt transmit a major metabolic branch. In skeletal muscle and adipose tissue, that branch helps move GLUT4 to the cell membrane, increasing glucose uptake by facilitated diffusion. GLUT4 is a membrane transport protein, not an insulin receptor. Insulin also favors glycogenesis in skeletal muscle and the liver, and inhibits lipolysis in adipose tissue. In the liver, suppression of glucose output involves enzyme regulation, gene expression, and indirect changes in substrate supply. Its relative direct and indirect contributions are more complex than a single Akt arrow. ^[ref]

Insulin is not a universal permission slip for glucose entry: red blood cells and much of the nervous system use uptake mechanisms that are not acutely dependent on insulin. Nor does the liver use the same GLUT4 switch as skeletal muscle. This is why reduced insulin action can change blood glucose dramatically without stopping all glucose uptake. ^[ref]

Diabetes can disrupt production, response, and counterregulation. Type 1 diabetes usually involves destruction of beta cells and severe loss of endogenous insulin; type 2 diabetes combines insulin resistance with insufficient beta cell compensation. High circulating insulin can therefore coexist with impaired insulin action. Inappropriate glucagon release can add to excessive liver glucose output, and the response to low blood glucose can also be impaired: "more glucagon" is not a complete description of diabetes. These distinctions explain mechanisms, rather than prescribe treatment. ^{[ref] [ref]}

The liver uses glucose sensing chiefly to regulate fuel storage and production, while pancreatic beta cells convert glucose availability into an endocrine signal. The comparison therefore includes transport, metabolism and allosteric control; it should not identify one transporter as the complete sensor in either tissue.

glucokinase phosphorylates glucose to glucose-6-phosphate in both hepatocytes and pancreatic beta cells. Unlike many other hexokinases, it is not strongly inhibited by its product and operates over a higher glucose range. Its monomeric enzyme nevertheless shows a sigmoidal steady-state response to glucose, arising from its kinetic conformational behaviour rather than cooperative binding between several subunits. A glucose half-saturation concentration in the physiological millimolar range makes its flux responsive to changing blood glucose, whereas a low-affinity constant cannot alone establish the in vivo sensing step without considering transport and downstream metabolism.

In beta cells, glucose metabolism through glycolysis and mitochondrial oxidation increases the cellular ATP-to-ADP state. ATP-sensitive potassium channels then close: ATP inhibits the Kir6.2 pore, while Mg-nucleotide effects mediated through SUR1 additionally regulate opening. Reduced potassium conductance produces depolarization, opening voltage-gated calcium channels. Calcium entry triggers exocytosis of insulin-containing secretory granules. Thus the channel senses nucleotides downstream of glucose metabolism; it does not bind extracellular glucose as its initiating ligand. Metabolic amplification and other signals also regulate the amount secreted, so this triggering pathway is necessary context rather than a complete description of every phase of insulin secretion.

glucokinase helps set the glucose threshold for that response. An activating glucokinase mutation associated with familial hyperinsulinism provides evidence that shifting the enzyme's glucose responsiveness can shift whole-body insulin control.^[ref] To separate this interpretation from altered expression, the variant's kinetics should be compared with the normal enzyme and its effect on secretion assessed at matched expression. Inhibiting the potassium channel downstream can bypass part of the sensing chain, whereas preventing calcium entry tests the final electrical-to-secretory coupling.

Glucose transport must be discussed with species in mind. GLUT2 is the prominent transporter in the classical rodent beta-cell model, but human beta cells use predominantly GLUT1 rather than sharing the same abundance of GLUT2. Direct comparison of human and rat preparations found much lower GLUT2 abundance in human cells while glucokinase retained a comparable influence on glucose utilization.^[ref] A transport step with capacity greater than phosphorylation can allow intracellular glucose availability to track the external supply, leaving glucokinase as a major metabolic control point. These observations argue against presenting rodent GLUT2 expression as a universal human sensing mechanism.

In the liver, GLUT2 supports rapid bidirectional facilitated transport. Hepatic glucokinase traps abundant glucose as glucose-6-phosphate, supplying glycogenesis and other metabolic pathways after feeding. glucokinase regulatory protein adds tissue-specific control: at low glucose it binds and sequesters glucokinase in the nucleus; increased glucose promotes release and cytoplasmic use. fructose-6-phosphate favours the inhibitory interaction, while fructose-1-phosphate antagonizes it, coordinating glucose trapping with nutrient context. Hormonal regulation of glucokinase expression adds a slower level of control. Unlike the beta-cell response, the immediate output is a change in hepatic metabolic flux, not release of insulin.

The liver also has an important direct glucose sensor in glycogen phosphorylase. Binding of glucose to liver glycogen phosphorylase a favours an inactive conformation and its dephosphorylation by protein phosphatase 1. Loss of phosphorylase-a activity switches off glycogenolysis and relieves its inhibitory influence on glycogen-synthase phosphatase activity, helping activate glycogen synthase. Glucose administration experiments observed phosphorylase inactivation preceding synthase activation, supporting an ordered switch rather than simultaneous independent responses.^[ref] This direct allosteric route is distinct from glucokinase-mediated metabolic sensing and complements insulin signalling. Together they suit an organ that must stop exporting and begin storing glucose when supply rises, while beta-cell sensing coordinates that transition across multiple tissues.